Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial.

Leukemia · 2022 · PMC9522585 · PMID 35974101

Europe PMC DOI

hedged sentence

0.4320

closest p · 8.6× alpha

0.4320

boldest claim

The sentences

did not reach statistical significancep = 0.432not close (p > 0.1)

4A and Supplementary Appendix ), but did not reach statistical significance ( p = 0.432).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.